Clinical trials: Clinically Isolated Syndrome (CIS)
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)
The goal of this observational study is to learn about the role of kappa free light chains (KFLC) in cerebrospinal fluid (CSF) in the diagnosis of multiple sclerosis (MS) and clinically isolated syndrome (CIS).
- Trial name
- PRO-KFLC (NCT07183020)
- Testing
- Oligoclonal bands and kappa free light chains (KFLC)
- Where
- Germany
- Volunteers
- 1,142 people
- Sponsor
- Skripuletz, Thomas Prof. Dr.
Clinically Isolated Syndrome
Longitudinal Study in Clinically Isolated Syndrome (CIS) Patients Treated With Interferon Beta
The aim of this study is to evaluate the role of cognitive disorders and quality of life in patients with CIS, considered as high risk to develop an MS, treated with interferon Beta.
- Trial name
- QUALICIS (NCT00819897)
- Where
- 17 sites in France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Sclerosis
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period
This is a prospective, multicentric, observational study with a 2 years recruitment period. The purpose of the study is to observe the multiple sclerosis (MS) progression of subjects since their first episode of neurological…
- Trial name
- NEO (NCT01112657)
- Where
- 6 sites in Taiwan
- Volunteers
- 154 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS), Clinically Isolated Syndrome (CIS)
Pregnancy Cohort in Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life.
- Trial name
- NCT05010902
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Prebiotic vs Probiotic in Multiple Sclerosis
This is a randomized crossover-designed study to explore the immunologic effects of Prebiotics, as opposed to direct supplementation with beneficial bacteria (Probiotics) in the immune system of patients with MS and Clinically…
- Trial name
- MS (NCT04038541)
- Testing
- Prebiotics (Prebiotin Prebiotic Fiber Stick Pac), Probiotics (Visbiome®)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Columbia University
Multiple Sclerosis, MS, Clinically Isolated Syndrome
Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis
A majority of patients with multiple sclerosis initially presents with a single demyelinating event, e.g. in the optic nerves, brain, brainstem or spinal cord, referred to as a clinically isolated syndrome (CIS).
- Trial name
- CIS-COHORT (NCT01371071)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Clinically Isolated System
Betaferon® Regulatory Post-Marketing Surveillance
To identify problems/questions about following items in the clinical practice using Betaferon 1. Unknown adverse event (especially serious adverse event) 2. Identification of adverse event occurred in the real practice 3.
- Trial name
- NCT01414816
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- South Korea
- Volunteers
- 355 people
- Sponsor
- Bayer
Multiple Sclerosis
MRI Hippocampal Microstructure and Episodic Memory in Early Multiple Sclerosis
Clinically isolated syndrome (CIS) can evolve into multiple sclerosis. In CIS patients, episodic memory is frequently impaired. Memory disorders could be preceded by microstructural abnormalities without visible atrophy in…
- Trial name
- Micro-MS (NCT03692975)
- Testing
- Clinical assessment, Neuropsychological evaluation, Psychological evaluation
- Where
- France
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Clinically Isolated Syndromes, Early Single Relapse of Multiple Sclerosis
Minocycline in Clinically Isolated Syndromes (CIS)
The aim of the trial is to demonstrate that 100 mg of oral minocycline twice daily reduces the conversion of CIS to McDonald Criteria MS (McDMS) by an absolute 25% as compared to placebo, over a 6 month follow-up period (primary…
- Trial name
- MinoCIS (NCT00666887)
- Testing
- Minocycline
- Where
- 12 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Dr. Luanne Metz
Multiple Sclerosis
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.
- Trial name
- ENCORE (NCT01167426)
- Testing
- Glatiramer Acetate 20 mg/0.5 mL
- Volunteers
- 148 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Sclerosis
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
The primary objective is to assess the effect of treatment with glatiramer acetate (GA) compared to placebo on the time to conversion to CDMS, as determined by Poser criteria (the occurrence of the second clinical attack) during…
- Trial name
- PreCISe (NCT00666224)
- Testing
- Glatiramer Acetate (DB), Glatiramer Acetate (OL)
- Volunteers
- 481 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Multiple Sclerosis, Clinically Isolated Syndrome
Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System
The Multiple Sclerosis Functional Composite (MSFC), a reliable and well-validated instrument, was developed as a multidimensional quantitative measure of neurologic disability in MS.
- Trial name
- MSPT (NCT04599023)
- Testing
- MSPT
- Where
- Switzerland
- Volunteers
- 182 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical…
- Trial name
- TOPIC (NCT00622700)
- Testing
- Teriflunomide
- Where
- 131 sites in United States, Australia and 19 more
- Volunteers
- 618 people
- Sponsor
- Sanofi